Neal Jay Meropol

Q: What Schools Are Affiliated With Neal Jay Meropol

Neal Jay Meropol is affiliated with the following schools: Temple University, University of Pennsylvania, George Washington University, Emory University, Indiana University, MD Anderson Cancer Center, University of Bristol, University of Texas Health Science Center at San Antonio, University of Oklahoma Health Sciences Center, Thomas Jefferson University, Duke University, Ghent University, Yale University, California South Bay University, Michigan State University, Georgetown University, Case Western Reserve University, Oregon Health & Science University

Neal Jay Meropol's AcademicInfluence.com Rankings

Neal Jay Meropol

Medical

#2879

World Rank

#3322

Historical Rank

Oncology

#190

World Rank

#196

Historical Rank

medical Degrees

Download Badge

Medical

Neal Jay Meropol's Degrees

Doctorate Medicine Harvard University

Why Is Neal Jay Meropol Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Neal Jay Meropol's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007) (2262)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. (2004) (1737)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. (2003) (1707)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. (2008) (1677)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (2007) (1178)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015) (722)
Delivering affordable cancer care in high-income countries. (2011) (656)
American Society of Clinical Oncology guidance statement: the cost of cancer care. (2009) (512)
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. (2009) (502)
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. (2010) (489)
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. (2009) (479)
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. (2001) (436)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. (2016) (435)
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. (2002) (384)
Activity of sunitinib in patients with advanced neuroendocrine tumors. (2008) (377)
Cost of cancer care: issues and implications. (2007) (353)
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (2005) (347)
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. (1999) (344)
Centralization of cancer surgery: implications for patient access to optimal care. (2009) (343)
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. (2014) (334)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. (2007) (324)
Patterns of breast carcinoma treatment in older women (2000) (289)
Global gene expression profiling of circulating tumor cells. (2005) (279)
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. (2005) (276)
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. (1998) (260)
Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial (1995) (259)
The continuum of care: a paradigm for the management of metastatic colorectal cancer. (2007) (247)
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. (2002) (244)
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. (2009) (231)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer (2007) (208)
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. (2003) (203)
Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma (2008) (198)
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. (2006) (195)
Changing patterns of bone and brain metastases in patients with colorectal cancer. (2005) (192)
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. (2000) (184)
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. (2001) (181)
Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer (2007) (180)
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. (2000) (173)
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. (2002) (173)
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. (2008) (169)
Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas (2001) (167)
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer (2016) (166)
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. (2003) (162)
Patients' decision-making process regarding participation in phase I oncology research. (2006) (161)
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. (2003) (152)
Gastric cancer. Clinical practice guidelines in oncology. (2006) (151)
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. (2002) (144)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin (1981) (134)
Impact of quality of life on patient expectations regarding phase I clinical trials. (2000) (125)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. (2006) (125)
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. (2003) (123)
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. (2013) (123)
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity (2003) (120)
Trends in Centralization of Cancer Surgery (2010) (114)
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. (2013) (110)
Barriers to clinical trial participation as perceived by oncologists and patients. (2007) (109)
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials (2003) (108)
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. (2006) (105)
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. (1992) (99)
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas (2003) (98)
Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing (1998) (91)
The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects (2011) (87)
Measuring and Predicting Surgeons’ Practice Styles for Breast Cancer Treatment in Older Women (2001) (86)
Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC) (2005) (85)
Circulating tumor cells: evolving evidence and future challenges. (2009) (82)
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. (1996) (82)
Targeting signal transduction pathways in colorectal cancer--more than skin deep. (2005) (80)
Proteomic Analyses of Pancreatic Cyst Fluids (2009) (76)
Modernizing Eligibility Criteria for Molecularly Driven Trials. (2015) (74)
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (2012) (73)
Cost implications of new treatments for advanced colorectal cancer (2009) (72)
Esophageal cancer. Clinical practice guidelines in oncology. (2006) (72)
A Randomized Trial of Generic Versus Tailored Interventions to Increase Colorectal Cancer Screening Among Intermediate Risk Siblings (2009) (70)
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) (2005) (70)
Patient Expectations of Benefit from Phase I Clinical Trials: Linguistic Considerations in Diagnosing a Therapeutic Misconception (2003) (68)
ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis (2004) (68)
End points in advanced colon cancer clinical trials: a review and proposal. (2007) (67)
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer (1996) (67)
Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab (2012) (67)
Cost concerns of patients with cancer. (2013) (66)
Loss of Methylthioadenosine Phosphorylase and Elevated Ornithine Decarboxylase Is Common in Pancreatic Cancer (2004) (62)
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. (2013) (61)
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model. (2003) (61)
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. (1996) (60)
Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. (2009) (60)
Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses. (2015) (59)
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. (2012) (59)
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. (2009) (58)
Cancer genetic risk assessment and referral patterns in primary care. (2009) (57)
Multiple Behavioral Risk Factors for Colorectal Cancer and Colorectal Cancer Screening Status (2007) (57)
Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. (2001) (57)
The relationships among knowledge, self‐efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial (2013) (57)
Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. (2016) (55)
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. (2008) (54)
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. (2007) (53)
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. (2007) (53)
Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting (2013) (52)
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. (2002) (51)
Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility study (2011) (49)
Comparative effectiveness of screening strategies for Lynch syndrome. (2015) (49)
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma (2016) (49)
Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy (2004) (49)
Expectations of Benefit in Early-Phase Clinical Trials: Implications for Assessing the Adequacy of Informed Consent (2008) (49)
The current status of toxicity protectants in cancer therapy. (1992) (48)
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. (2011) (47)
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. (1999) (46)
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. (2002) (46)
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. (2008) (45)
Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. (2005) (44)
Patient and provider characteristics that affect the use of axillary dissection in older women with Stage I–II breast carcinoma (2002) (44)
The management of infectious and noninfectious anorectal complications in patients with leukemia. (1996) (44)
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours (2015) (43)
Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. (2006) (43)
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. (2010) (42)
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. (2010) (41)
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma (2011) (39)
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials (2005) (39)
Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer (2012) (38)
Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials (2007) (38)
Oral fluoropyrimidines in the treatment of colorectal cancer. (1998) (38)
Value and Cancer Care: Toward an Equitable Future (2010) (37)
ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. (2004) (36)
Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer. (2019) (36)
Ongoing challenge of stage II colon cancer. (2011) (35)
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. (2019) (35)
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. (2013) (34)
Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report (2006) (34)
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? (2012) (33)
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors (2009) (33)
Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. (2019) (32)
A Web‐based communication aid for patients with cancer (2013) (32)
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (2015) (31)
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. (2012) (31)
Antibacterial Activity of Ceftriaxone (Ro 13-9904), a β-Lactamase-Stable Cephalosporin (1981) (31)
Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. (2015) (31)
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. (2000) (30)
In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2 (2011) (30)
Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model. (1998) (29)
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors (1997) (29)
Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study. (2014) (29)
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. (2016) (28)
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers (2020) (28)
National treatment trends among older patients with T1-localized renal cell carcinoma. (2017) (28)
Gastric Cancer Clinical Practice Guidelines. (2006) (27)
Esophageal Cancer Clinical Practice Guidelines. (2006) (27)
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice (2019) (27)
Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer (1995) (27)
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (2007) (26)
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. (2012) (25)
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer (2000) (25)
Requirement of hydrophilic amino-terminal residues for granulocyte-macrophage colony-stimulating factor bioactivity and receptor binding. (1992) (25)
An Exploration of Relative Health Stock in Advanced Cancer Patients (2004) (25)
Preoperative Chemoradiation in the Management of Adenocarcinoma of the Body of the Pancreas (2002) (25)
RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer (2008) (25)
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. (2014) (24)
A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study (2012) (24)
A phase II study of high-dose bevacizumab in combination with irinotecan , 5-fluorouracil , leucovorin , as initial therapy for advanced colorectal cancer : results from the eastern cooperative oncology group study E 2200 (2006) (24)
Prognostic factors affecting survival in patients with colorectal carcinomatosis. (1999) (24)
NCCN practice guidelines for upper gastrointestinal carcinomas (1959) (24)
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture (2006) (24)
Nurses' attitudes toward clinical trials at a comprehensive cancer center. (2001) (24)
3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy (2007) (23)
Knowledge and Attitudes about Microsatellite Instability Testing among High-Risk Individuals Diagnosed with Colorectal Cancer (2007) (23)
Effects of a Decision Support Intervention on Decisional Conflict Associated with Microsatellite Instability Testing (2011) (22)
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. (2005) (22)
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response (2017) (22)
Decisional Conflict among Patients Who Accept or Decline Participation in Phase I Oncology Studies (2008) (21)
A new era for the systemic therapy of neuroendocrine tumors. (2012) (21)
Metastatic colorectal cancer: advances in biochemical modulation and new drug development. (1995) (21)
Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials (2007) (20)
Decision Tree–Based Modeling of Androgen Pathway Genes and Prostate Cancer Risk (2011) (20)
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. (1996) (20)
Phase II Trial of Preoperative Chemoradiation With a Hyperfractionated Radiation Boost in Locally Advanced Rectal Cancer (2006) (20)
Coincident Kaposi sarcoma and T‐cell lymphoma in a patient with the Wiskott‐Aldrich syndrome (1992) (20)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors (2004) (19)
Trial Prospector: Matching Patients with Cancer Research Studies Using an Automated and Scalable Approach (2014) (19)
Cost Sharing and Hereditary Cancer Risk: Predictors of Willingness-to-Pay for Genetic Testing (2014) (19)
Erratum: Constructs of burden of illness in older patients with breast cancer: A comparison of measurement methods (Health Services Research (December 2001) 36:6 PART 1 (1085-1107)) (2007) (19)
An internet method to assess cancer patient information needs and enhance doctor-patient communication: A pilot study (2009) (18)
Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. (1997) (18)
Prognostic Significance of Patient-Reported Outcomes in Cancer. (2020) (18)
Barriers to participation in cancer prevention clinical trials (2010) (18)
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative. (2011) (18)
Patient-physician discordance in goals of care for patients with advanced cancer. (2019) (18)
Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. (2010) (17)
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer (2014) (17)
The Role of Qualitative and Quantitative Analysis of F18-FDG Positron Emission Tomography in Predicting Pathologic Response Following Chemoradiotherapy in Patients with Esophageal Carcinoma (2012) (17)
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. (2011) (17)
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. (2019) (17)
Seizures associated with leucovorin administration in cancer patients. (1995) (17)
Perspectives on the Cost of Cancer Care (2007) (17)
Does comparative effectiveness research promote rationing of cancer care? (2014) (16)
The Role of Oncology Nurses in Discussing Clinical Trials. (2017) (16)
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. (1998) (16)
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer (1999) (16)
Diabetes mellitus induced by low-dose interleukin-2 (1996) (16)
A pilot study of cryochemotherapy for hepatic metastases from colorectal cancer. (1996) (16)
ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU. (2006) (15)
Factitious Illness: An Exploration in Ethics (2015) (15)
Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer (1997) (15)
A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. (2017) (14)
ASCO Addresses the Rising Cost of Cancer Care. (2009) (14)
Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. (2016) (14)
How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors (2007) (14)
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104) (2017) (14)
Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors (1997) (14)
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? (2004) (14)
Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States. (2016) (13)
A simulation model of colorectal cancer surveillance and recurrence (2014) (13)
A pilot study of early hospital discharge in adult patients with fever and neutropenia. (1994) (12)
Chemoprevention of colorectal cancer (2001) (12)
Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. (2004) (12)
Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200. (2006) (12)
A renewed call for equipoise. (2007) (12)
Developing and sustaining an effective and resilient oncology careforce: Opportunities for action. (2019) (12)
Esophageal cancer. (2020) (12)
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. (2014) (12)
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. (2013) (11)
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors (2012) (11)
A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). (2012) (11)
Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists (2018) (11)
Current status of gene expression profiling to assist decision making in stage II colon cancer. (2014) (11)
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer (2004) (11)
Knowledge, Attitudes, and Self-efficacy as Predictors of Preparedness for Oncology Clinical Trials (2014) (11)
A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135). (2009) (11)
Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research Group. (1998) (11)
Influence of Diabetes on the Interpretation of PET Scans in Patients With Esophageal Cancer. (2009) (11)
High-dose chemotherapy with autologous stem cell support for breast cancer. (1992) (10)
Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient (2009) (10)
Telomerase is Frequently Activated in Tumors with Microsatellite Instability (2004) (10)
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis (2016) (10)
The clinical development of paclitaxel and the paclitaxel/carboplatin combination. (1998) (10)
Unsupported off-label chemotherapy in metastatic colon cancer (2012) (10)
Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts. (2020) (10)
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). (2019) (10)
A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma (2007) (10)
The significance of circulating tumor cells as prognostic markers for colon cancer. (2009) (10)
Phase II study of ZD1694 in patients with advanced gastric cancer. (1996) (10)
Phase II trial of preoperative chemoradiation with a hyperfractionated rt boost in locally advanced rectal cancer (2001) (10)
Identifying cluster subtypes for intentions to have colorectal cancer screening among non-compliant intermediate-risk siblings of individuals with colorectal cancer. (2009) (10)
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. (2018) (9)
Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort study (2019) (9)
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. (1996) (9)
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors. (2018) (9)
Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200 (2007) (9)
Validation of diagnosis codes to identify side of colon in an electronic health record registry (2019) (9)
Comparative effectiveness research to inform medical decisions: the need for common language. (2012) (8)
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen (2004) (8)
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203) (2018) (8)
Recruitment Strategies for Nurse Enrollment in an Online Study. (2019) (8)
Pancreatic cancer (2000) (8)
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. (1999) (8)
Identification of barriers to clinical trials: The impact of education level. (2011) (8)
Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. (2019) (8)
ACA Medicaid expansion association with racial disparity reductions in timely cancer treatment. (2021) (7)
Addressing Patients’ Priorities as a Strategy to Improve Value (2016) (7)
Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies (2007) (7)
Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. (2016) (7)
Turning point for colorectal cancer clinical trials. (2006) (7)
Phase I I, R andomized T rial C omparing B evacizumab P lus Fluorouracil ( FU)/Leucovorin ( LV) W ith F U/LV A lone i n Patients W ith M etastatic C olorectal C ancer (2003) (7)
Using electronic health record data to identify comparator populations for comparative effectiveness research (2020) (7)
E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors (2018) (7)
Oral therapy for colorectal cancer: how to choose. (2000) (7)
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. (2019) (7)
The imperative to address the cost of oncology care. (2013) (7)
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer. (2011) (7)
Payment for cancer care: time for a new prescription. (2014) (7)
A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials (2021) (7)
Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. (1995) (7)
Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. (2009) (6)
Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on quality-adjusted life expectancy and costs. (2011) (6)
Relationship between phase I study duration and symptom burden (2018) (6)
Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgery. (1996) (6)
Direct cost-survival analysis of therapies for metastatic colorectal cancer. (2006) (6)
Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. (2014) (6)
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies (2015) (5)
Amifostine and chemoradiation therapy: ASCO responds. (2003) (5)
Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC). (2011) (5)
Implementing an Electronic End-of-Life Chemotherapy Utilization Measure. (2019) (5)
Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. (2011) (5)
Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. (2017) (5)
P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients (2019) (5)
An intravenous phase I trial of PV701, a replication-competent virus, in the treatment of patients with advanced solid cancers (2001) (5)
Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. (2004) (5)
Development of new agents for the treatment of advanced colorectal cancer. (2003) (5)
Facilitating Enrollment in a Cancer Registry Through Modified Consent Procedures: A Pilot Study (2012) (5)
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed (2002) (5)
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial. (1997) (5)
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. (2021) (4)
Changing patterns of colorectal cancer metastases: A 10-year retrospective review. (2004) (4)
Impact of antibiotics (ABX) on overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (aNSCLC) and melanoma (aMel) treated with first-line immune checkpoint inhibition (ICI). (2019) (4)
A neutralizing monoclonal antibody binds to an epitope near the amino terminus of murine granulocyte-macrophage colony-stimulating factor. (1991) (4)
Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) (2019) (4)
Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment (2020) (4)
The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. (2019) (4)
Screening for Lynch Syndrome in the General Population–Letter (2011) (4)
Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase in a phase II study of capecitabine plus irinotecan in patients with metastatic colorectal cancer. (2004) (4)
Progress in the Application of Machine Learning Algorithms to Cancer Research and Care. (2021) (4)
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates (2017) (4)
Textbook of Uncommon Cancer, Third Edition (2006) (4)
Carcinoembryonic Antigen-Still More to Learn From the Real World. (2017) (4)
Predictive Biomarkers and Personalized Medicine Association betweenVEGFSplice IsoformsandProgression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab (2012) (3)
Drug development in pancreatic cancer (2002) (3)
Psychosocial barriers to clinical trial participation as perceived by oncologists and patients (2005) (3)
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop (2021) (3)
30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors (2004) (3)
Digital Health Applications in Oncology: An Opportunity to Seize (2022) (3)
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors (2020) (3)
Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US. (2018) (3)
Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform (2021) (3)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. (2004) (3)
Delivering Affordable Cancer Care in High-income Countries: a Lancet Oncology Commission (2011) (3)
Changing patterns of colorectal cancer metastases: A 10-year retrospective review (2004) (3)
Phase I clinical and pharmacokinetic study of the farnesyl transferase inhibitor BMS-214662 administered intravenously for five consecutive days in patients with advanced malignancies. (2004) (3)
Circulating endothelial cells (CEC) and circulating tumor cells (CTC) in patients (pts) with metastatic colorectal cancer (mCRC). (2006) (3)
Poster Viewing PresentationRadiation Therapy in Gallbladder Cancer Treatment: The Fox Chase Cancer Center Experience (2007) (2)
Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. (2015) (2)
Phase II pharmacodynamic study of the fibroblast activation protein inhibitor Val-boro-Pro in patients with metastatic colorectal cancer. (2006) (2)
Health policy: Overcoming cost barriers to clinical trial participation (2016) (2)
Patient (Pt) and oncologist (MD) discordance in goals of care in end of life (EOL) decision making. (2018) (2)
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer. (2011) (2)
Contemporary national trends of prostate cancer screening among privately insured patients in the United States. (2015) (2)
Targeted therapies in colorectal cancer: Complications and management (2006) (2)
A phase I study of capecitabine in combination with yttrium-90 labeled resin microspheres (SIR-Spheres) in patients (pts) with advanced cancer. (2011) (2)
Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. (2019) (2)
Tendency to serious sequelae of infection with the human immunodeficiency virus in sibships with hemophilia. (1989) (2)
ASCO Outlines Minimum Standards and Exemplary Attributes for Research Sites: Previews Tools to Be Provided. (2008) (2)
Real-world trends in first-line checkpoint inhibitor use (CPI) in advanced urothelial cell carcinoma (aUC). (2019) (2)
Predic tors of Long-Term Outcomes in Older Breast Cancer (2003) (2)
Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients. (2018) (2)
Abstract 3303: Development and initial validation of a prognostic score based on structured data from EHRs (2019) (2)
Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors. (2015) (2)
Metastatic colorectal cancer (mCRC) patterns of care: Implications for clinical trial design (2007) (2)
Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials (RCTs). (2019) (2)
Efficacy Endpoints of RTOG 0247: A Randomized Phase II Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer (2015) (2)
Colorectal Cancer Incidence Among Adults Younger Than 50 Years-Understanding Findings From Observational Studies of Lower Gastrointestinal Endoscopy. (2022) (2)
Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients. (2019) (2)
Randomized trial of a web-based nurse education intervention to increase discussion of clinical trials (2021) (2)
Assessing the impact of a targeted educational initiative on colorectal cancer lymph node retrieval: A Fox Chase Cancer Center Partners' quality initiative. (2016) (2)
Development and validation of a model to predict outcomes of colon cancer surveillance (2019) (2)
A National Study of Oncology Nurses Discussing Cancer Clinical Trials With Patients (2019) (1)
Treatment Choices by Seriously III Patients (1998) (1)
A phase I study of etirinotecan pegol in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. (2014) (1)
Gastrointestinal cancer committee (2001) (1)
In reply [3] (2007) (1)
A pilot study to determine the feasibility of a customized low glycemic load diet in patients with stage I-III colorectal cancer. (2020) (1)
A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancer. (2021) (1)
The Effect of Gender and Dose on the Development of Symptomatic Cardiac Toxicity after Chemoradiotherapy for Esophageal Carcinoma (2008) (1)
Trial prospector: An automated clinical trials eligibility matching program. (2013) (1)
Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer. (2018) (1)
The impact of the Affordable Care Act on treatment of testicular cancer. (2017) (1)
Assessing real-world biomarker testing rates in metastatic colon cancer. (2020) (1)
Diverse cancer prevention needs in a population seeking risk assessment for gastrointestinal (GI) cancers. (2009) (1)
Adjuvant therapy report card: Patients with stage II/III colon cancer grade their oncologists. (2009) (1)
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma (2004) (1)
Prognostic value of patient-reported outcomes (PROs) in advanced cancer. (2018) (1)
Colorectal cancer: looking forward. (2005) (1)
Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL). (2018) (1)
3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy (2007) (1)
Cancer Patient Information and Communication Needs Survey (2016) (1)
Opportunities for using big data to advance cancer care. (2018) (1)
Which adjuvant systemic treatments (AdjRx) would medical oncologists (MOs) wish to receive if they had colon cancer (CCa)? A survey of 150 physicians (2008) (1)
Fibroblast activation protein and focal adhesion kinase: novel stromal therapeutic targets in pancreatic adenocarcinoma. (2004) (1)
Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2). (2012) (1)
Importance of incorporating measures of attitude in planning and evaluating nursing education. (2018) (1)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. (2001) (1)
De-adoption of epidermal growth factor receptor (EGFR) inhibitors following recommendations for KRAS testing to guide treatment of metastatic colorectal cancer (mCRC). (2012) (1)
Cardiac toxicity associated with dose and gender in patients undergoing chemoradiation for esophageal carcinoma. (2012) (1)
Health care worker attitudes about clinical trials at a comprehensive cancer center. (2013) (1)
Efficacy and safety of panitumumab across five clinical studies in patients with metatastic colorectal cancer. (2007) (1)
Trial prospector update: A point of care automated clinical trials matching application. (2018) (1)
Aligning goals of care with aggressiveness at end of life (EOL). (2018) (1)
A randomized, controlled trial of structured palliative care versus standard supportive care for patients enrolled on phase I clinical trials. (2020) (1)
Development of a dashboard for end-of-life care at an academic hospital. (2018) (1)
Correlation of molecular response as measured by 18-FDG PET with outcome after chemo-radiation in patients with esophageal carcinoma (2010) (1)
Assessing the treatment quality of elderly patients with stage III colon cancer in a large community oncology network: A Fox Chase Cancer Center Partners (FCCCP) quality initiative (2008) (0)
Cancer patients’ trade-offs for efficacy, toxicity, and cost. (2012) (0)
Predicting benefit from adjuvant therapy in colon cancer (2007) (0)
Molecular Targeting of Colorectal Cancer (2008) (0)
Retrospective analysis of phase 1 study duration and symptom burden among patients at a comprehensive cancer center. (2016) (0)
Subject Index Vol. 68, 2005 (2005) (0)
Association of Aurora kinase A and epidermal growth factor receptor (EGFR) gene copy number with overall survival in KRAS wild-type patients with metastatic colorectal cancer. (2010) (0)
A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer. (1996) (0)
Methylated vimentin (mVim) DNA in blood as a novel biomarker in colorectal cancer: A retrospective study. (2015) (0)
Impact of Metformin and Statin Use on Esophageal Cancer Survival: 499 (2016) (0)
Contents Vol. 68, 2005 (2005) (0)
Adherence to and determinants of guideline‐recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice (2021) (0)
Predicted benefit of alternative post-treatment surveillance strategies in stage II and III colon cancer survivors. (2016) (0)
Perceived Risk and Severity of Colorectal Cancer Measure (2016) (0)
Clinical Studies Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN 8054 , a Small-Molecule Inhibitor of Aurora A Kinase (2011) (0)
Socioeconomic Factors, Urological Epidemiology and Practice Patterns Re: Delivering Affordable Cancer Care in High-Income Countries (2011) (0)
Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) (2019) (0)
Rectal Cancer Outcome Study Based on Multiple NRG Oncology Clinical Trials with Random Survival Forests (2017) (0)
Clinical benefits and costs of new treatments for advanced colorectal cancer (2009) (0)
A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors. (2010) (0)
PCN93 COST-EFFECTIVENESS OF MULTI-GENE PANEL SEQUENCING FOR PATIENTS WITH ADVANCED MELANOMA (2019) (0)
Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer 1 (2002) (0)
117 Negative post-treatment 18-FDG pet scans may not predict pathologic complete response in patients with rectal cancer undergoing neoadjuvant chemoradiation (2006) (0)
1075 : A Phase II Trial of Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Resectable or Unresectable Non-Metastatic Pancreatic Cancer (2006) (0)
The Health Stock Risk Adjustment Model (1998) (0)
Understanding the non-curative potential of palliative chemotherapy: Do patients hear what they want to hear? (2017) (0)
PET Imaging in Qualitative Assessment of Response to Chemoradiation in Patients with Esophageal Cancer (2006) (0)
The Blum Article Reviewed (1997) (0)
OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLYADVANCED RECTAL CANCER (2012) (0)
Use of predictive models (PMs) in colorectal cancer (CRC) for diagnosis of Lynch syndrome (LS): A process measure for quality of care. (2012) (0)
KRAS mutational status is associated with clinical response in patients with metastatic colorectal cancer receiving panitumumab monotherapy (2007) (0)
Longitudinal Quality of Life (QOL) and Patient-Reported Bowel Function in RTOG 0247 (2011) (0)
Randomized P hase I T rial o f R ecombinant H uman Keratinocyte G rowth F actor P lus C hemotherapy: P otential R ole as M ucosal P rotectant (2003) (0)
1003 POSTER The use of molecular imaging to help predict response and disease-free survival following pre-operative chemoradiation in patients with adenocarcinoma of the rectum (2007) (0)
Correction: Screening for Lynch Syndrome in the General Population—Letter (2011) (0)
Mortality A ssociated W ith I rinotecan P lus B olus Fluorouracil/Leu covorin: S ummary F indings o f a n Independent P anel (2001) (0)
Phase I I a nd P harmacodynamic S tudy o f t he Farnesyltransfer ase I nhibitor R 115777 a s I nitial T herapy i n Patients W ith M etastatic P ancreatic A denocarcinoma (2003) (0)
Colorectal carcinoma: overview of clinical research and management 2011. (2011) (0)
Knowledge and beliefs about colorectal cancer screening in patients with colonic polyps (2001) (0)
Age-related real-world outcomes for patients (pts) with metastatic colorectal cancer (mCRC). (2018) (0)
Abstract B7: Use of risk assessment services and predictive genetic testing (PGT) for hereditary gastrointestinal (GI) cancers: How do men and women differ? (2010) (0)
Update in Hematology and Oncology: Evidence Published in 2012 (2013) (0)
Disparities in Access and Treatment of Patients With High-Risk Prostate Cancer: Results From a Population-Based Cohort (2016) (0)
Understanding patient expectations in early-phase clinical trials (2007) (0)
Colorectal Cancer Screening Pros and Cons Measure (2016) (0)
Phlebitis Induced by Parenteral Treatment with Flucloxacillin and Cloxacillin: a Double-Blind Study (1981) (0)
Impact o f Q uality o f L ife o n P atient E xpectations Regarding P hase I C linical T rials (2000) (0)
Let's Focus on Value. (2008) (0)
Would you do it again? The perspectives of patients as they receive and recover from adjuvant therapy for stage II/III colon cancer. (2010) (0)
A New Era for Real-World Evidence (2019) (0)
The Olszewski/Grossbard/Kozuch article reviewed (2005) (0)
PRM55 A New Approach to Modeling Cancer Recurrence and Follow-Up (2011) (0)
Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. (2006) (0)
RACIAL VARIATION IN THE REFUSAL OF INITIAL TREATMENT PLAN AMONG MEN DIAGNOSED WITH LOCALIZED PROSTATE CANCER: PD09‐02 (2017) (0)
Qualitative assessment of response to chemo-radiation with FDG-PET imaging in patients with esophageal cancer (2007) (0)
A Phase I Study of Docetaxel, Cisplatin, 5-Fluorouracil and Leucovorin (2005) (0)
Impact of Oncology Care Model (OCM) reporting requirements on quality of care. (2019) (0)
Talking with patients about dying. (2013) (0)
Gastric Cancer NCCN Gastric Cancer Panel Members Continue (2001) (0)
Normal Tissue Complication Probability (NTCP) Modeling of Cardiac Toxicity in Patients with Esophageal Cancer Undergoing Chemoradiation (2009) (0)
The Role of Qualitative Analysis of F18-FDG Positron Emission Tomography in Predicting Pathologic Response following Chemoradiotherapy in Patients with Esophageal Carcinoma (2009) (0)
Abstract 2740: Decision tree-based modeling of androgen pathway genes and prostate cancer risk (2011) (0)
Perceptions o f P atients a nd P hysicians R egarding P hase I Cancer C linical T rials: I mplications f or P hysician-Patien t Communication (2003) (0)
Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC). (2020) (0)
Reply to S. Sciallero et al (2010) (0)
Carboplatin-based chemotherapy (C) versus immunotherapy (IO) in metastatic urothelial carcinoma (mUC). (2019) (0)
Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC). (2018) (0)
Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers (2019) (0)
It's time for a prospective study (2014) (0)
Predictors o f L ong-Term O utcomes i n O lder B reast C ancer Survivors: P erceptions V ersus P atterns o f C are (2003) (0)
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. (2009) (0)
Does Physician Description of Therapeutic Options Influence Breast Cancer Patient Treatment Choice (1995) (0)
Development and validation of a model to predict outcomes of colon cancer surveillance (2019) (0)
Smirnov, D. A. et al. Global gene expression profiling of circulating tumor cells. Cancer Res. 65, 4993-4997 (2005) (0)
Use of clinical history (CH) for Lynch syndrome (LS) risk assessment: An economic decision analysis. (2012) (0)
Colon cancer recurrence: insights from the interface between epidemiology, laboratory science, and clinical medicine. (2012) (0)
Commentary (Denlinger/Meropol): The Horizon of Antiangiogenic Therapy for Colorectal Cancer (2005) (0)
Tu1178 Use of Epidural Analgesia for Esophagectomy in Esophageal Cancer Is Associated With Better Survival (2016) (0)
Phase I a nd P harmacokinetic T rial o f G emcitabine i n Patients W ith H epatic o r R enal D ysfunction: C ancer a nd Leukemia G roup B 9 565 (2000) (0)
Physician-patient communication in phase I cancer trials. Authors' reply (2004) (0)
Comparative E ff ectiveness of Carboplatin / Pemetrexed With Versus Without Bevacizumab for Advanced NonsquamousNon – Small Cell LungCancer (2019) (0)
PCN19 USE OF THE EUROQOL VISUAL ANALOGUE SCALE IN ASSESSING LONGITUDINAL CHANGES IN QUALITY OF LIFE IN CANCER PATIENTS: A COMPARISON WITH SUBSCALES OF THE MEDICAL OUTCOMES SURVEY SHORT FORM-36 (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Neal Jay Meropol?

Neal Jay Meropol is affiliated with the following schools: